Low-dose Bactrim Safe with Methotrexate in AAV
A high proportion of GPA patients receive pneumocystis prophylaxis, usually with TMP-SMX (Bactrim), and drug interactions are always a concern.
A high proportion of GPA patients receive pneumocystis prophylaxis, usually with TMP-SMX (Bactrim), and drug interactions are always a concern.
Prof Weyland started by explaining that giant cell arteritis (GCA) and Takayasu Arteritis (TA) are granulomatous forms of arteritis.
The pathogenesis between microscopic gut inflammation leading to the development of Crohn’s disease and sacroiliitis has been poorly understood. Dr. Debusschere, et al sought to understand this important link between IBD and axial SpA.
There are two things I learned in rheumatology fellowship.
Never burn any bridges because everyone in rheumatology knows each other
Rheumatologists like their food
Check out this compilation of our ACR Day 1 videocasts merged into one 59 minute podcast !
https://soundcloud.com/rheumnow/rheumnow-acr-2017-san-diego-day-1
Curtis and colleagues presented a plenary session that analyzed the duration of drug holidays and the risk of subsequent fractures (FX) in women starting bisphosphonates (BP).
We know that cardiovascular disease (CVD) is the leading cause of death in RA and that traditional risk factors do not fully account for increased risk.
From Dr. Michelle Petri’s lecture on Antiphospholipid Syndrome Updates at ACR17 Review Course on Saturday, I learned that there is now a new class of diseases called the complementopathies. This was the first time I heard of this term; how many patients did I misdiagnose who really had this and what are the ICD10 codes?!
Professor Rosenbaum is well known for his expertise in rheumatic eye disease and he gave a great summary of how to approach your patient having a red eye.
Prof Robert Inman gave a great summary of the state of the art in reactive arthritis (ReA).
With the increasing use of biologic therapies to treat rheumatic disease has come an awareness of a small but real risk of developing de novo autoimmune disease.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.